Answers are grounded in this paper and cite their sources.
Autoimmune diseases are chronic and intractable and caused by the disruption of immune tolerance mechanisms and the imbalance of immune homeostasis. Conventional treatments and targeted drugs have the limitations such as insufficient safety and low response rates. By unique advantages of immunomodulation and tissue repair, an innovative treatment, Mesenchymal stem cells (MSCs) have gradually matured. Nevertheless, they are still facing the problems like instable function and low homing efficacy in clinical translation. Interferon-γ (IFN-γ) preconditioned can effectively optimize efficacy of MSCs, with core mechanisms including:Binding to IFN-γ receptors (IFNγR) on the surface of MSCs to activate the JAK-STAT signaling pathway and trigger the transcription of immunomodulation related genes;Significantly upregulating the expression of IDO1, PD-L1, and TGF-β, which regulate the activation and function of Tregs, T cells and B cells to reestablish immune homeostasis, downregulating the expression of chemokine receptors CXCR4 and CCR7, shifting the function of MSCs from active migration to local retention and enhancing local therapeutic efficacy at lesion sites. This paper systematically organizes the activation, immunoregulatory and homing optimization mechanism of IFN-γ preconditioned MSCs, summarizes the advantages and challenges and provides a theoretical reference for basic research and clinical translation in the treatment of autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Yiru Dong (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: